Protagonist Therapeutics, Inc., a biopharmaceutical company that specializes in developing peptide-based drugs for hematology and blood disorders, as well as inflammatory and immunomodulatory diseases, has announced that it is currently working on a number of drugs that are in Phase II clinical trials. These drugs include Rusfertide (PTG-300), an injectable hepcidin mimetic that is being developed for treating erythrocytosis, iron overload, and other blood disorders. The company is also developing JNJ-2113, an orally delivered investigational drug that acts as a biological pathway blocker, and is currently in Phase II clinical trials for treating moderate-to-severe plaque psoriasis. Additionally, Protagonist is working on PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is also in Phase II clinical trials, but for treating inflammatory bowel disease. Protagonist Therapeutics, Inc. has a license and collaboration agreement with Janssen Biotech, Inc. The company, which was founded in 2006, is headquartered in Newark, California.
Protagonist Therapeutics, Inc.'s ticker is PTGX
The company's shares trade on the NASDAQ stock exchange
They are based in Newark, California
There are 51-200 employees working at Protagonist Therapeutics, Inc.
It is https://www.protagonist-inc.com/
Protagonist Therapeutics, Inc. is in the Healthcare sector
Protagonist Therapeutics, Inc. is in the Biotechnology industry
The following five companies are Protagonist Therapeutics, Inc.'s industry peers: